May Wang

Dr. Wang heads all alliance management and business development for the company. She has been instrumental in engaging with, negotiating, executing, and very actively liaising with all the development partners, including AstraZeneca, Nestlé Health Science, and Eli Lilly.

Prior to joining HUTCHMED in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head of Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation, and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011 for treatment of HCV infection.

Dr. Wang has numerous patents, published more than 50 peer-reviewed articles, and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.